Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock. According to the … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering”

The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever Phase I in pediatric patients FDA modified the trial design to designate overall survival as the trial’s primary endpoint The market for brain tumor therapies is expected to grow at a CAGR of 10% and … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently approved Investigational New Drug (“IND”) application involving its lead product candidate Berubicin for the treatment … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced that it has received US Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application on its lead product candidate Berubicin for the treatment … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval of IND Application for Brain Cancer Drug Candidate Berubicin”

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent “Want Money Got Money” podcast. Hosted by author, founder, speaker and CEO Sam Kamani, the podcast series shares stories, secrets and skills of the world’s most brilliant and interesting start-up founders and investors. During the podcast, Climaco talked about recent research … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on ‘Want Money Got Money’ Podcast”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE”